NCT02243787View on ClinicalTrials.gov

Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2015

Conditions
Plaque Psoriasis
Interventions
DRUG

COVA322

OTHER

Placebo

Trial Locations (2)

Unknown

Charité research organisation, Berlin

SCIderm and Clinical Trial Center North, Hamburg

Sponsors

Lead Sponsor

Covagen
All Listed Sponsors
lead

Covagen

INDUSTRY